Kessler Investment Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Kessler Investment Group’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-30	Closed	-$15.8K	–	175
2025 Q2	$15.8K	Hold	30	–	–	0.01%	126
2025 Q1	$19K	Hold	30	–	–	0.01%	126
2024 Q4	$21.4K	Hold	30	–	–	0.01%	108
2024 Q3	$31.5K	Hold	30	–	–	0.02%	105
2024 Q2	$31.5K	Hold	30	–	–	0.02%	103
2024 Q1	$28.9K	Hold	30	–	–	0.02%	98
2023 Q4	$26.3K	Hold	30	–	–	0.02%	105
2023 Q3	$24.7K	Hold	30	–	–	0.02%	92
2023 Q2	$21.6K	Hold	30	–	–	0.02%	99
2023 Q1	$24.6K	Hold	30	–	–	0.02%	108
2022 Q4	$22K	Hold	30	–	–	0.02%	94
2022 Q3	$21K	Hold	30	–	–	0.02%	111
2022 Q2	$18K	Sell	30 -30	-50%	-$19.5K	0.02%	111
2022 Q1	$42K	Buy	+60	New	+$38K	0.02%	107

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Kessler Investment Group's REGN Position: Q3 2025 in Review

Kessler Investment Group sold out of Regeneron Pharmaceuticals (REGN) in Q3 2025, closing a stake of 30 shares — an estimated $15.8K sold.

Kessler Investment Group first reported a position in REGN in Q1 2022 and held it in 14 quarters. The position peaked at $42K in Q1 2022. 1,245 funds tracked by Wall St. Rank hold REGN as of Q3 2025.

Kessler Investment Group reported no remaining Regeneron Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Kessler Investment Group sold 30 Regeneron Pharmaceuticals shares in Q3 2025, an estimated $15.8K.
Kessler Investment Group first reported a position in Regeneron Pharmaceuticals in Q1 2022 and held it in 14 quarters.
Kessler Investment Group's Regeneron Pharmaceuticals position peaked at $42K in Q1 2022.
1,245 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2025.

Based on Kessler Investment Group's 13F filing for Q3 2025, filed 9 Oct 2025.